🔗 Share this article

As the United States undertakes historic changes to its immunization recommendations, one figure has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by casting doubt on coronavirus vaccinations in the pandemic and has concentrated on potential fatalities after Covid vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Vaccine Schedule

Public health authorities planned to reveal radical revisions to the pediatric vaccine schedule in December, aligning the US with the Danish vaccine program, sources say – a significant shift that would place the US out of step with a large portion of the international standard with little proof for public health gain. This reveal has been delayed until the coming year.

Instead of the top vaccines chief, Tracy Beth Høeg is set to present at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to lead the center this calendar year.

A New Direction at the FDA

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a greater focus upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for ending some pediatric immunization guidelines in the US to become more similar to the Danish model, a nation with nationalized medicine and a population approximately the population of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on immunizations – traditionally the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Doubts Over Expertise

Dr. Høeg has no obvious track record in drug development, oversight or administrative roles, which has been customary for past heads of the biologics center. She has served at the FDA as a key advisor to the agency head and the vaccine center since March.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, said a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in running a major agency. She lacks background in drug approvals.”

Former heads of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she lacks the type of experience that previous people who headed CBER have had.”

This division has an vast workload at the FDA, Woodcock pointed out.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office approves numerous generic drugs. There’s a biosimilars program, over-the-counter program and so forth, and each of these need to be looked after,” Dr. Woodcock explained. “The area you overlook, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a major leadership aspect to the position, which supervises in excess of 5,000 personnel. “It is a massive leadership role, if you execute it properly,” Woodcock concluded.

Response and Controversial Programs

In response to inquiries about Dr. Høeg's fitness for the role and whether this assignment signifies more teamwork among FDA leaders on immunizations, a press secretary stated that the “questions rely on inaccurate assumptions”.

“This background is consistent with the duties of her job,” the representative said, noting the period Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg takes over the agency head's recently launched fast-track approval initiative, a controversial one-day drug-approval program that reportedly worried her former heads. “How are these drugs being selected for this voucher program? Who makes the calls?” Dr. Howard asked. “There is a lot of confidentiality happening at the agency right now.”

Broadly speaking, he stated, “the Food and Drug Administration appears to be shifting towards laxer oversight of most medications, except for vaccines.”

Documented Track Record on Vaccines

Concerning vaccines, Høeg has a more documented, if problematic, track record, some experts said. She published a analysis using unconfirmed crowd-sourced reports to estimate the rate of myocarditis after COVID-19 immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the current government encompassed revising rules for recently developed shots and halting “non-essential” vaccines, she stated after the election on a podcast. At the agency, Dr. Høeg has allegedly proposed barring young men from receiving COVID-19 vaccinations.

“She’s an complete dogmatist who starts off with her conclusions and tailors the evidence to fit the data in a extremely disingenuous, dishonest fashion,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Høeg joined fellow contrarians, {like|